REDUCEDT+30
Karlin Daniel
Definium Therapeutics Inc · NASDAQ
−10,853 sh · $396.9K
Filed 29 Sept 2026SEC Form 4view source
Two Sigma Investments
13F filer
$22.7M
1,201,610 sh
Duquesne Family Office
13F filer
$16.8M
356,600 sh
Barrow Robert
US insider
$1.2M
739,427 sh
Sullivan Mark
US insider
$513.8K
110,949 sh
Karlin Daniel
US insider
$396.9K
189,147 sh
Roberts Brandi
US insider
$123.5K
121,623 sh
Wiley Matthew T.
US insider
$113.3K
121,903 sh
Krebs Andreas
US insider
$57.9K
1,629 sh
Vallone Carol A
US insider
$38.6K
1,086 sh
Karlin Daniel
Definium Therapeutics Inc · NASDAQ
−10,853 sh · $396.9K
Sullivan Mark
Definium Therapeutics Inc · NASDAQ
−14,051 sh · $513.8K
Roberts Brandi
Definium Therapeutics Inc · NASDAQ
−3,377 sh · $123.5K
Barrow Robert
Definium Therapeutics Inc · NASDAQ
−31,550 sh · $1.2M
Wiley Matthew T.
Definium Therapeutics Inc · NASDAQ
−3,097 sh · $113.3K
Vallone Carol A
Definium Therapeutics Inc · NASDAQ
+1,086 sh · $38.6K
Krebs Andreas
Definium Therapeutics Inc · NASDAQ
+1,629 sh · $57.9K
Sullivan Mark
Definium Therapeutics Inc · NASDAQ
+125,000 sh
Wiley Matthew T.
Definium Therapeutics Inc · NASDAQ
+125,000 sh
Karlin Daniel
Definium Therapeutics Inc · NASDAQ
+200,000 sh